Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non–Small Cell Lung Cancer Patients

Ragusa, Mark; Vannucci, Jacopo; Ludovini, Vienna; Bianconi, Fortunato; Treggiari, Stefano; Tofanetti, Francesca Romana; Flacco, Antonella; Colella, Renato; Sidoni, Angelo; Crinò, Lucio; Puma, Francesco

doi:10.1097/coc.0b013e31827a7e7a

Cited by 16 publications

(21 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study is the first large-scale study to compare the prognosis and clinicopathological features between EGFR Del-19 and L858R in only stage I and II lung adenocarcinoma. Most of the previous reports that compared the characteristics of EGFR Del-19 and L858R included stage III or IV disease, which require multimodality treatment [5,11,20,23,29]. Thus, the analyses in those studies might be too complicated for an objective comparison of Del-19 and L858R.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma

et al. 2017

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 91%

“…Over the past decade, several studies have examined the association between postoperative prognosis and the status of EGFR mutation in lung cancer [5,7,11,12,[18][19][20][21][22][23][24][25][26][27].…”

Section: Discussionmentioning

confidence: 99%

Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma

et al. 2017

View full text Add to dashboard Cite

“…A retrospective study enrolled 311 patients with resected lung adenocarcinoma (high‐risk stage IB–IIIA), and the EGFR mutation rate was only 28.3% . Another study enrolled 230 patients with stage I–III NSCLC, and the EGFR mutation rate was only 16.9% (39/230) . Similarly, an EGFR mutation rate of only 20% was detected among 1118 patients with stage I–III lung adenocarcinoma, enrolled from 2002 to 2009 .…”

Section: Discussionmentioning

confidence: 99%

EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China

Zhang

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundEGFR‐tyrosine kinase inhibitors play an important role in the treatment of advanced non‐small cell lung cancer (NSCLC). EGFR mutations in advanced NSCLC occur in approximately 35% of Asian patients and 60% of patients with adenocarcinoma. However, the frequency and type of EGFR mutations in early‐stage lung adenocarcinoma remain unclear.MethodsWe retrospectively collected data on patients diagnosed with lung adenocarcinoma tested for EGFR mutation. Early stage was defined as pathological stage IA–IIIA after radical lung cancer surgery, and advanced stage was defined as clinical stage IIIB without the opportunity for curative treatment or stage IV according to the American Joint Committee on Cancer Staging Manual, 7th edition.ResultsA total of 1699 patients were enrolled in this study from May 2014 to May 2016; 750 were assigned to the early‐stage and 949 to the advanced‐stage group. Baseline characteristics of the two groups were balanced, except that there were more smokers in the advanced‐stage group (P < 0.001). The total EGFR mutation rate in the early‐stage group was similar to that in the advanced‐stage group (53.6% vs. 51.4%, respectively; P = 0.379). There was no significant difference in EGFR mutation type between the two groups. In subgroup analysis of smoking history, there was no difference in EGFR mutation frequency or type between the early‐stage and advanced‐stage groups.ConclusionEarly‐stage and advanced‐stage groups exhibited the same EGFR mutation frequencies and types.

show abstract

“…Oral EGFR-TKI treatment is an alternative option for patients with advanced NSCLC with unsuccessful primary chemotherapy. In tumor cells, EGFR is often mutated or overexpressed, resulting in tumor cell apoptosis inhibition and tumor growth promotion 12. Thus, EGFR-TKIs counteract this by blocking EGFR expression and promoting apoptosis 13.…”

Section: Discussionmentioning

confidence: 99%

Correlation between epidermal growth factor receptor tyrosine kinase inhibitor efficacy and circulating tumor cell levels in patients with advanced non-small cell lung cancer

He¹,

Li²,

Jiang³

et al. 2016

OTT

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to investigate the correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and circulating tumor cell (CTC) levels in patients with advanced non-small cell lung cancer (NSCLC). The efficacy of EGFR-TKIs in reducing CTC counts in patients with advanced NSCLC was studied.Patients and methodsA total of 66 patients with advanced NSCLC were enrolled and divided into two groups (those with high CTC counts and those with low CTC counts) based on the patients’ median CTC counts. All the patients were treated with an EGFR-TKI, and the treatment efficacy and prognoses were compared.ResultsThe treatment efficacies were 53.3% (16/30) and 27.8% (10/36) for the low CTC group and high CTC group, respectively, and this difference was statistically significant (P<0.05). The median overall survival was 22.8 months (95% confidence interval [CI]: 18.9–26.8 months) for the low CTC group and 18.3 months (95% CI: 2.9–8.2 months) for the high CTC group. The median progression-free survival was 11.5 months (95% CI: 8.1–15 months) and 5.6 months (95% CI: 2.9–8.2 months) for the low and high CTC groups, respectively, and the difference was statistically significant (P<0.05).ConclusionThe CTC count can be used as an index for predicting the EGFR-TKI effect on patients with advanced NSCLC. Efficacy and prognosis of EGFR-TKI treatment and CTC count were considered important, and the CTC count could be used to predict the efficacy of EGFR-TKI treatment and prognosis of advanced NSCLC. The change in CTC expression levels can be used as an index for evaluating the prognosis of patients with advanced NSCLC.

show abstract

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non–Small Cell Lung Cancer Patients

Abstract: EGFR and KRAS mutations are frequent in ADCs and are not prognostic factors for survival. EGFR mutations could be used to identify patients suitable for adjuvant treatment with targeted therapy resulting in potentially improved outcomes.

Cited by 16 publications

References 8 publications

Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma

Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma

EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China

Correlation between epidermal growth factor receptor tyrosine kinase inhibitor efficacy and circulating tumor cell levels in patients with advanced non-small cell lung cancer

Contact Info

Product

Resources

About